Treatment cycle

A typical heat treatment cycle, as illustrated in Figure 1, comprises both nucleation and crystallization temperature holds, but some glass-ceramics are designed to nucleate and/or crystallize during the ramp itself, eliminating the need for multiple holds. 

Fig. 1. Heat treatment cycle for a glass-ceramic material.

Cleaning, the removal of unwanted matter, is the beginning of the treatment cycle for metal. The unwanted matter may be carbon smut, welding flux, ink, oxidation products, oil, fingerprints, or other material. Cleaners may be classified as solvent-based or aqueous. Within the aqueous class there are many subclasses, the most important of which are the alkaline cleaners. There are also a variety of ways to apply cleaners. As of the mid-1990s, solvent-based cleaner usage is declining. 

Tests in a Clj + Oj mixture at 427°C have shown that the worst elements for promoting susceptibility are Al, Sn, Cu, V, Cr, Mn, Fe and Ni, while the least harmful are Zr, Ta and Mo. a-phase alloys are generally more susceptible than )3-phase alloys. Heat treatment has not been examined extensively, but some heat treatments render some a-alloys more susceptible or change the mode of fracture. The general effect will depend upon the alloy and the heat-treatment cycle. Subsequent cold work can sometimes considerably lower susceptibility. Failure times decrease as either the testing temperature or initial stress value is raised. 

The last three examples indicate the importance of analysis of the required air treatment cycle on the psychrometric chart as a guide to the methods which can be adopted and those which are not possible. This analysis can also provide optimization of energy flows for a process. 

A backup contraceptive should be used for the first week of the first treatment cycle. 

As expected, HTMAB made a respectable showing in these experiments. Trioctylmethylammonium chloride (TOMAC) and trioctylmetliylammonium bromide (TOMAB) outperformed all other catalysts. It was postulated that the three octyl groups were the proper length for solvation of the polymer while at the same time small enough to avoid sterically hindering the reaction. In order to determine if TOMAB could be used to catalyze PET depolymerization for more than one treatment cycle, the catalyst was recovered upon completion of one treatment and added to a second run for 60 min. Tetraethylammonium hydroxide (TEAOH) was studied as a catalyst in order to demonstrate the effect of hydroxide ion as a counterion. The percent PET conversion for the second cycle was 85.7% compared to a conversion of 90.4% for the first treatment cycle. 

Due to the variable appearance of genital warts, treatment maybe based on the size, site, and morphology of the lesions. Additionally, switching to alternate therapy is appropriate if there has been no response after three treatment cycles. 

Large warts Treat warts greater than 10 mm in diameter with surgical excision. Use imiquimod for three to four treatment cycles to reduce the number of warts and improve surgical outcomes. Fifty percent reduction in wart size after four treatment cycles warrants continued use of imiquimod until warts clear or eight cycles have been completed less than 50% reduction warrants surgical excision or other ablative therapy. 

Dose intensity refers to the amount of drug administered per unit of time, which can be achieved by increasing dose, decreasing time, or both. Dose density is one way of achieving dose intensity by decreasing time between treatment cycles. 

Reexposure There is limited information to support any recommendations for reexposure to lepirudin. Of 13 patients reexposed in 2 studies, one experienced a mild allergic skin reaction during the second treatment cycle. 

First day start - For first day start, apply the first patch during the first 24 hours of the menstrual period. If therapy starts after day 1 of the menstrual cycle, a nonhormonal back-up contraceptive (eg, condoms, spermicide, diaphragm) should be used concurrently for the first 7 consecutive days of the first treatment cycle. 

Hyperkalemia Yasmin contains the progestin drospirenone that has antimineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to a 25 mg dose of spironolactone. Yasmin should not be used in patients with conditions that predispose to hyperkalemia. Women receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium should have their serum potassium level checked during the first treatment cycle. 

CTCL Extracorporeal Inject 200 meg into the photoactivation bag during collection cycle using the UVAR photopheresis system, 2 consecutive days every 4 wk for a minimum of 7 treatment cycles. 

Pure podophyllotoxin (podofilox) is approved for use as a 0.5% podophyllotoxin preparation (Condylox) for application by the patient in the treatment of genital condylomas. The low concentration of podofilox significantly reduces the potential for systemic toxicity. Most men with penile warts may be treated with less than 70 n-L per application. At this dose, podofilox is not routinely detected in the serum. Treatment is self administered in treatment cycles of twice-daily application for 3 consecutive days followed by a 4-day drug-free period. Local adverse effects include inflammation, erosions, burning pain, and itching. 

---